

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁶: C07D 209/08, 401/10, 409/10, 413/10, A61K 31/40		A1	(11) International Publication Number: WO 95/06637 (43) International Publication Date: 9 March 1995 (09.03.95)
(21) International Application Number: PCT/EP94/02663 (22) International Filing Date: 9 August 1994 (09.08.94) (30) Priority Data: 9318325.9 3 September 1993 (03.09.93) GB 9318337.4 3 September 1993 (03.09.93) GB 9322251.1 28 October 1993 (28.10.93) GB 9322252.9 28 October 1993 (28.10.93) GB 9325753.3 16 December 1993 (16.12.93) GB (71) Applicant (for all designated States except US): SMITHKLINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): GASTER, Laramie, Mary [GB/GB]; SmithKline Beecham Pharmaceuticals, Coldharbour Road, The Pinnacles, Harlow, Essex CM19 5AD (GB). DUCKWORTH, David, Malcolm [GB/GB]; SmithKline Beecham Pharmaceuticals, Coldharbour Road, The Pinnacles, Harlow, Essex CM19 5AD (GB). JENKINS, Sarah, Margaret [GB/GB]; SmithKline Beecham Pharmaceuticals, Coldharbour Road, The Pinnacles, Harlow, Essex CM19 5AD (GB). WYMAN, Paul, Adrian [GB/GB]; SmithKline			Beecham Pharmaceuticals, Coldharbour Road, The Pinnacles, Harlow, Essex CM19 5AD (GB). (74) Agent: GIDDINGS, Peter, John; Corporate Intellectual Property, SmithKline Beecham, Mundells, Welwyn Garden City, Herts AL7 1EY (GB). (81) Designated States: JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> = US 5,696,122
(54) Title: INDOLE AND INDOLINE DERIVATIVES AS 5HT1D RECEPTOR ANTAGONISTS			
(57) Abstract Novel indole and indoline derivatives, processes for their preparation, pharmaceutical compositions containing them and their use as medicaments are disclosed.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.


AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

INDOLE AND INDOLINE DERIVATIVES AS 5HT_{1D} RECEPTOR ANTAGONISTS


The present invention relates to novel urea derivatives, processes for their preparation, and pharmaceutical compositions containing them.

- 5 EPA 0 533 266/7/8 disclose a series of benzanilide derivatives which are said to possess 5HT_{1D} receptor antagonist activity. These compounds are alleged to be of use in the treatment of various CNS disorders such as depression.


- A structurally distinct class of compounds have now been discovered and have been found to exhibit 5HT_{1D} antagonist activity. In a first aspect, the present invention
 10 therefore provides a compound of formula (I) or a salt thereof:



- 15 in which
 R is a group of formula (i):



- in which P¹ is a phenyl or a 5 to 7-membered heterocyclic ring containing 1 to 3
 20 heteroatoms selected from oxygen, nitrogen or sulphur; and
 R¹ and R² are independently hydrogen, halogen, C₁₋₆alkyl, C₁₋₆alkoxy, hydroxyC₁₋₆alkyl, acyl, nitro, trifluoromethyl, cyano, SR⁵, SOR⁵, SO₂R⁵, SO₂NR⁵R⁶, CO₂R⁵, CONR⁵R⁶, CONR⁵(CH₂)_xCO₂R⁶, NR⁵R⁶, NR⁵CO₂R⁶, CR⁵=NOR⁶, where R⁵ and R⁶ are independently hydrogen or C₁₋₆alkyl and x is 1 to 3;
 25 or R is a group of formula (ii):



- in which P² is phenyl or biphenyl;
 30 P³ is phenyl or a 5 to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected

from oxygen, nitrogen or sulphur;

A is a bond or a group $(\text{CH}_2)_p\text{-R}^8\text{-(CH}_2)_q$ where R^8 is oxygen, S(O)_m where m is 0 to 2, carbonyl, CO_2 or CH and p and q are independently 0 to 3; and

R^1 and R^2 are as defined above in formula (i);

- 5 R^3 is hydrogen, halogen, hydroxy, C_{1-6} alkyl or C_{1-6} alkoxy;
n is 1 or 2;

R^4 is hydrogen or C_{1-6} alkyl; and

B is $\text{-CHR}^9\text{CHR}^{10}\text{-}$ or $\text{-CR}^9=\text{CR}^{10}\text{-}$ where R^9 and R^{10} are independently hydrogen or C_{1-6} alkyl.

- 10 C_{1-6} alkyl groups, whether alone or as part of another group, may be straight chain or branched.

The groups P^1 , P^2 , and P^3 can be aromatic or saturated heterocyclic rings.


Examples of aromatic heterocyclic rings include thienyl, furyl, pyrrolyl, triazolyl, diazoly, isothiazolyl, oxadiazolyl, isoxazolyl, thiadiazolyl, pyridyl, pyrimidyl and pyrazinyl.

- 15 Examples of saturated rings include piperidine, morpholine and piperazine rings. Each of the groups P^1 , P^2 , and P^3 can be linked to the remainder of the molecule via a carbon atom or, when present, a nitrogen atom.

When R is a group of formula (i) P^1 is preferably phenyl, R^1 is preferably halogen and R^2 is preferably C_{1-6} alkyl, for example methyl.

- 20 Preferred groups of formula (ii) include those in which P^2 and P^3 are both phenyl and A is oxygen and those in which P^2 is biphenyl, A is a bond and P^3 is a 5 to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen or sulphur. More preferably P^3 is a 5-membered ring containing 3 heteroatoms, in particular a 1,2,4-oxadiazol-3-yl group. When R is a group of formula (ii) R^1 and R^2 are preferably C_{1-6} alkyl in particular methyl. When P^2 is a biphenyl group one or more R^2
- 25 substituents can be present.

Most preferably R is a group of formula (ii) having the following structure:



30

Suitably R^3 is hydrogen, halogen, hydroxy, C_{1-6} alkyl or C_{1-6} alkoxy. Preferably R^3 is C_{1-6} alkoxy such as methoxy.

Preferably n is 1.

Suitably R⁴ is hydrogen or C₁₋₆alkyl. Preferably R⁴ is hydrogen or C₁₋₄alkyl such as methyl.

Preferably R⁹ and R¹⁰ are both hydrogen such that the group B forms part of an indole or indoline ring.

5 Particularly preferred compounds include:

- 1-[3-methyl-4-(4-pyridyl)phenyl]-2,3-dihydro-5-methoxy-6-(4-methyl-1-piperazinyl)-1H-indole,
 1-(4-bromo-3-methylbenzoyl)-2,3-dihydro-5-methoxy-6-(4-methyl-1-piperazinyl)-1H-indole,
 10 1-(4-bromo-3-methylbenzoyl)-5-methoxy-6-(4-methyl-1-piperazinyl)-1H-indole,
 2,3-dihydro-5-methoxy-6-(4-methyl-1-piperazinyl)-1-[2'-bromo-3'-methoxythiophene-4'-ylcarbonyl]indole,
 2,3-dihydro-5-methoxy-6-(4-methyl-1-piperazinyl)-1-[4'-phenoxybenzoyl]indole,
 2,3-dihydro-5-methoxy-1-[4-(2-methyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)benzoyl]-6-(4-methyl-1-piperazinyl)-1H-indole,
 15 5-methoxy-1-[4-(2-methyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)benzoyl]-6-(4-methyl-1-piperazinyl)-1H-indole, or
 2,3-dihydro-5-methoxy-1-[4-(2-methyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)benzoyl]-6-(1-piperazinyl)-1H-indole,
 20 or pharmaceutically acceptable salts thereof.

Preferred salts of the compounds of formula (I) are pharmaceutically acceptable salts. These include acid addition salts such as hydrochlorides, hydrobromides, phosphates, acetates, fumarates, maleates, tartrates, citrates, oxalates, methanesulphonates and p-toluenesulphonates.

25 Certain compounds of formula (I) are capable of existing in stereoisomeric forms. It will be understood that the invention encompasses all geometric and optical isomers of the compounds of formula (I) and the mixtures thereof including racemates.

In a further aspect the present invention provides a process for the preparation of a compound of formula (I) which comprises:

30


(a) coupling a compound of formula (II):

R-COL

35

(II)

in which R is as defined in formula (I) and L is a leaving group with a compound of formula (III):




(III)

5

in which R^3 , R^4 , B and n are as defined in formula (I);

(b) for compounds where R is a group of formula (ii), A is a bond and P^2 is a phenyl group, reaction of a compound of formula (IV):




10

(IV)

in which R^2 , R^3 , R^4 and n are as defined in formula (I), P^2 is phenyl and X is a leaving group with a nucleophile R^1-P^3 where R^1 and P^3 are as defined in formula (I);

15

(c) reaction of a compound of formula (V):



20

(V)


in which R, R^3 , B and n are as defined in formula (I) with a compound of formula (VI):

25




in which R^4 is as defined in formula (I) and Hal is halogen, or

(d) for compounds where R is a group of formula (ii) and A is a bond, reaction of a compound of formula (VII):



(VII)


in which P^2 , R^2 , R^3 , R^4 , B and n are as defined in formula (I) and Y is halogen or a group $-\text{OSO}_2\text{CF}_3$ with a compound of formula (VIII):



(VIII)


in which R^1 and P^3 are as defined in formula (I), or

(e) for compounds where R is a group of formula (ii) and A is a bond, reaction of a compound of formula (IX):



(IX)

in which P^2 , R^2 , R^3 , R^4 , B and n are as defined in formula (I) with a compound of formula (X):



(X)

in which R^1 and P^3 are as defined in formula (I) and Y is as defined in formula (VII), and optionally after any of the above processes:

- converting a compound of formula (I) into another compound of formula (I)
- forming a pharmaceutically acceptable salt.

5 Suitable activated carboxylic acid derivatives of formula (II) include acyl halides and acid anhydrides. Activated compounds of formula (II) can also be prepared by reaction of the corresponding carboxylic acid with a coupling reagent such as carbonyldiimidazole, dicyclohexylcarbodiimide or diphenylphosphorylazole. Preferably the group L is halo, particularly chloro.

10 A compound of formula (II) is typically reacted with a compound of formula (III) in an inert organic solvent such as DMF, THF or dichloromethane at ambient or elevated temperature in the presence of a base such as triethylamine or pyridine. In the case of indoles a base such as KO^tBu is required.

15 Compounds of formula (II) can be prepared from a compound of formula (XI):



(XI)

20 in which R is as defined in formula (I) using standard procedures. For example acid chlorides can be prepared by reaction with phosphorous pentachloride, oxalyl chloride or thionyl chloride. Acid anhydrides can be prepared by reaction with a suitable acid anhydride, for example trifluoroacetic anhydride.

25 Reaction of a compound of formula (IV) with a nucleophile R^1-P^3 is preferably carried out in a suitable solvent such as dimethylformamide in the presence of a strong base such as sodium hydride. Preferably the leaving group X is halo, in particular fluoro. Preferably the group R^2 is an electron withdrawing group, for example nitro, $COCH_3$ or cyano, in the ortho or para-positions relative to the group X.

30 Reaction of a compound of formula (V) with a compound of formula (VI) is suitably carried out in an alcohol or nitrile solvent with an optional base or, alternatively, in a non-polar solvent such as chlorobenzene in the absence of base. Suitably, the reactions are carried out at ambient or elevated temperature, preferably at the reflux temperature of the reaction mixture.

35 Reaction of compounds of formula (VII) and (VIII) and reaction of compounds of formulae (IX) and (X) can be carried out in the presence of a transition metal catalyst such as $Pd(PPh_3)_4$ in a solvent such as an ether in the presence of a base such as an alkali metal carbonate or bicarbonate, for example sodium carbonate or bicarbonate, at ambient or elevated temperature.

Intermediate compounds of formulae (III), (IV), (V), (VI), (VII), (VIII), (IX), (X) and (XI) are commercially available or can be prepared using standard procedures such as those outlined in EPA 533266/7/8.

5 It will be appreciated by those skilled in the art that it may be necessary to protect certain reactive substituents during some of the above procedures, for example when the group R^4 is a hydrogen atom. Suitable protecting groups and methods for their attachment and removal are conventional in the art of organic chemistry, such as those described in Greene T.W. 'Protective groups in organic synthesis' New York, Wiley (1981).

10 For example, secondary amines can be protected as benzyl, benzyloxycarbonyl or trityl derivatives. These groups can be removed by conventional procedures.

Carboxylic acid groups can be protected as esters. Aldehyde or ketone groups can be protected as acetals, ketals, thioacetals or thioketals. Deprotection is achieved using standard conditions.

15 Compounds of formula (I) can be converted into further compounds of formula (I) using standard techniques. For example, in the case wherein R^4 is hydrogen, it is possible to introduce a C_{1-6} alkyl group by conventional alkylation using 1 molar equivalent of a C_{1-6} alkyl halide and 1 molar equivalent of a suitable base in an inert solvent. Compounds of formula (I) in which R^1 or R^2 are acid groups can be esterified using normal
20 procedures.

5HT_{1D} Antagonists, and in particular the compounds of the present invention, may therefore be of use in the treatment of CNS disorders such as mood disorders, including depression, seasonal effective disorder and dysthymia; anxiety disorders, including
25 generalised anxiety, panic disorder, agoraphobia, social phobia, obsessive compulsive disorder and post-traumatic stress disorder; memory disorders, including dementia, amnesic disorders and age-associated memory impairment; and disorders of eating behaviours, including anorexia nervosa and bulimia nervosa. Other CNS disorders include Parkinson's disease, dementia in Parkinson's disease, neuroleptic-induced Parkinsonism and tardive dyskinesias, as well as other psychiatric disorders.

30 5HT_{1D} Antagonists, and in particular compounds of the present invention, may also be of use in the treatment of endocrine disorders such as hyperprolactinaemia, in the treatment of vasospasm (particularly in the cerebral vasculature) and hypertension, as well as disorders in the gastrointestinal tract where changes in motility and secretion are involved. They may also be of use in the treatment of sexual dysfunction.

35 Therefore, the present invention, provides a compound of general formula (I) or a physiologically acceptable salt or solvate thereof for use in therapy.

The present invention also provides a compound of general formula (I) or a physiologically acceptable salt or solvate thereof for use in the treatment of the aforementioned disorders.

5 In another aspect the invention provides the use of a compound of general formula (I) or a pharmaceutically acceptable salt or solvate thereof for the manufacture of a medicament for the treatment of the aforementioned disorders.

10 In a further aspect the invention provides a method of treating the aforementioned disorders which comprises administering an effective amount to a patient in need of such treatment of a compound of general formula (I) or a pharmaceutically acceptable salt or solvate thereof.

In particular the invention provides a compound of general formula (I) or a physiologically acceptable salt or solvate thereof for use in the treatment or prophylaxis of depression.

15 It will be appreciated by those skilled in the art that the compounds according to the invention may advantageously be used in conjunction with one or more other therapeutic agents, for instance, different antidepressant agents.

The present invention also provides a pharmaceutical composition, which comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

20 A pharmaceutical composition of the invention, which may be prepared by admixture, suitably at ambient temperature and atmospheric pressure, is usually adapted for oral, parenteral or rectal administration and, as such, may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable or infusible solutions or suspensions or suppositories. Orally administrable
25 compositions are generally preferred.

Tablets and capsules for oral administration may be in unit dose form, and may contain conventional excipients, such as binding agents, fillers, tableting lubricants, disintegrants and acceptable wetting agents. The tablets may be coated according to methods well known in normal pharmaceutical practice.

30 Oral liquid preparations may be in the form of, for example, aqueous or oily suspension, solutions, emulsions, syrups or elixirs, or may be in the form of a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and, if desired,
35 conventional flavourings or colorants.

For parenteral administration, fluid unit dosage forms are prepared utilising a compound of the invention or pharmaceutically acceptable salt thereof and a sterile

vehicle. The compound, depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions, the compound can be dissolved for injection and filter sterilised before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents are dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilisation cannot be accomplished by filtration. The compound can be sterilised by exposure to ethylene oxide before suspension in a sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.

The composition may contain from 0.1% to 99% by weight, preferably from 10 to 60% by weight, of the active material, depending on the method of administration.

The dose of the compound used in the treatment of the aforementioned disorders will vary in the usual way with the seriousness of the disorders, the weight of the sufferer, and other similar factors. However, as a general guide suitable unit doses may be 0.05 to 1000 mg, more suitably 1.0 to 200 mg, and such unit doses may be administered more than once a day, for example two or three a day. Such therapy may extend for a number of weeks or months.

When administered in accordance with the invention, no unacceptable toxicological effects are expected with the compounds of the invention.

The following Examples illustrate the preparation of compounds of the invention.

Intermediate 1**N-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl] aminoacetaldehyde dimethyl acetal**

5

A suspension of 4-methoxy-3-(4-methyl-1-piperazinyl) benzenamine (5g, 0.023 mol) in ethanol (150 ml) and dimethoxyethanal (9.5g, 1.2eq) was hydrogenated over 10% Palladium on charcoal (3 g) at standard temperature and pressure for 3 h. The suspension was filtered through kieselguhr, washed with methanol and evaporated to give a pale yellow oil. Purification by Fcc, eluting with 2% methanol/dichloromethane afforded the title compound (6.64 g, 95%).

10

¹H NMR (250MHz, CDCl₃) δ :

15

2.38 (3H, s), 2.63 (4H, br s), 3.11 (4H, br s), 3.21 (2H, d, J = 6), 3.42 (6H, s), 3.81 (3H, s), 4.58 (1H, t, J = 2), 6.27 (1H, m), 6.32 (1H, m), 6.72 (1H, d, J = 6).

Intermediate 2**1-H-[5-methoxy-6-(4-methyl-1-piperazinyl)]indole**

20

A solution of intermediate 1, (6.6g, 0.02 mol) in TFA (27 ml) at 0° C was treated with TFAA (27 ml) under an argon atmosphere. More TFA (40 ml) was added and the reaction was heated to reflux for 48h. The solution was evaporated to dryness and the residue taken up in ethyl acetate, washed with saturated sodium bicarbonate solution, and water (3x), dried (Na₂SO₄) and evaporated to give the title compound as a brown solid (1.21g, 71%).

25

¹H NMR (250 MHz, CDCl₃) δ :

30

2.70 (3H, s), 2.67 (4H, br s), 3.12 (4H, br s), 3.90 (3H, s), 6.45 (1H, m), 7.0 (1H, s), 7.08 (1H, s), 7.12 (1H, m), 8.21 (1H, br s).

Intermediate 3**2,3-Dihydro-5-methoxy-6-(1-piperazinyl)-1H-indole**

Intermediate 2 (0.5g, 2mmol) in glacial acetic acid was treated with sodium
5 cyanoborohydride (0.75g, 1.2mmol) at room temperature with stirring for 1h. The
mixture was diluted with water and basified with 10% aq. NaOH. The product was
extracted into dichloromethane (3x), dried (Na₂SO₄), filtered and evaporated to give the
title compound as a brown solid (0.49g, 99%).

10 ¹H NMR (250 MHz, CDCl₃) δ :

2.72 (3H, s), 3.0 (2H, t, J = 6), 3.15 (4H, br s), 3.23 (4H, br s), 3.55 (2H, t, J = 6), 3.80
(3H, s), 6.39 (1H, s), 6.77 (1H, s)

15 Intermediate 4**2,3-Dihydro-5-methoxy-6-(1-piperazinyl)-1H-indole**

A stirred solution of intermediate 3 (280 mg, 1.1 mmole) in 1,2-dichloroethane (15 ml) at
room temperature under argon was treated with 1-chloroethyl chloroformate (0.31 ml, 2.8
20 mmole). The mixture was kept at room temperature for 1h, then treated with
diisopropylethylamine (0.25 ml, 1.5 mmole) and heated under reflux for 2h. The reaction
mixture was concentrated *in vacuo*, the residue treated with methanol (10 ml) and heated
under reflux for 1h. The solution was concentrated under vacuum and the residue basified
with 10% Na₂CO₃ solution (20 ml) and extracted with dichloromethane (2 x 20 ml). The
25 combined extract was dried (Na₂SO₄) and concentrated under vacuum to afford the title
compound as a brown oil (270 mg, 100%).

¹H NMR (250 MHz) CDCl₃

30 δ : 6.72 (1H, s), 6.38 (1H, s), 3.79 (3H, s), 3.52 (2H, t), 2.6-3.1 (12H, m).

Intermediate 5**2,3-Dihydro-5-methoxy-6-(4-tert-butoxycarbonyl-1-piperazinyl)-1H-indole**

35 A stirred solution of intermediate 4 (270 mg, 1.1 mmole) and triethylamine (0.30 ml, 2.2
mmole) in dichloromethane (8 ml) was treated with a solution of di-tert-butyl dicarbonate
(200 mg, 1.0 mmole) in dichloromethane (5 ml) and the mixture kept at room temperature

for 3h, then treated with 10% Na₂CO₃ solution (10 ml) and extracted with dichloromethane (2 x 15 ml). The combined extract was dried (Na₂SO₄), concentrated under vacuum, and the residue chromatographed on silica gel eluting with ethyl acetate to afford the title compound as a beige solid (130 mg, 38%).

5

¹H NMR (250 MHz) CHCl₃

δ : 6.74 (1H, s), 6.34 (1H, s), 3.80 (3H, s), 3.48-3.64 (7H, m), 2.90-3.05 (6H, m), 1.48 (9H, s)

10

Example 1

15 1-(4-bromo-3-methylbenzoyl)-2,3-dihydro-5-methoxy-6-(4-methyl-1-piperazinyl)-1H-indole

A solution of intermediate 3 (220 mg, 0.89 mmol), in dry THF (24 ml) and water (24 ml) containing sodium hydroxide (0.546g) was treated with a solution of 4-bromo 3-methyl benzoyl chloride (870mg, 1.58 mmol) in dry THF (10 ml). The resulting mixture was stirred at room temperature for 4 h then water was added and the mixture was extracted with dichloromethane (3x). The organic layers were combined, dried (Na₂ SO₄), filtered and concentrated *in vacuo* to give the title compound as a yellow foam. Purification by FCC eluting with 1% methanol/dichloromethane gave the product as a pale yellow oil (0.5g, 12%).

25

¹H NMR (250 MHz, CDCl₃) δ :

2.38 (3H, s), 2.42 (3H, s), 2.67 (5H, br s), 3.02 - 3.17 (5H, m), 3.87 (3H, s), 3.98 (1H, br s), 4.21 (1H, br s), 6.72 (1H, s), 7.21 (1H, d, J = 6), 7.41 (1H, s), 7.61 (1H, d, J = 6), 7.98 (1H, br s).

30

Example 2

35 1-[3-methyl-4-(4-pyridyl)phenyl]-2,3-dihydro-5-methoxy-6-(4-methyl-1-piperazinyl)-1H-indole

A mixture of example 1 (0.13g, 0.29 mmol), 4-pyridinylboronic acid (0.04g, 0.29 mmol),

tetrakis (triphenylphosphine) palladium (0) (15 mg) and aqueous sodium carbonate (2N; 1.5 ml) and DME (5 ml) was heated at reflux under argon for 48 h. The reaction mixture was then cooled to room temperature, added to water and extracted with dichloromethane (3x). The combined organic layers were dried (Na₂SO₄) and concentrated *in vacuo* to give an oil. Purification by FCC, eluting with 2% methanol/dichloromethane afforded the title compound (0.07g, 35%).

¹H NMR (250 MHz, CDCl₃) δ :

2.32 (3H, s), 2.38 (3H, s), 2.68 (5H, br s), 3.07-3.18 (5H, br s), 3.85 (3H, s), 4.10 (1H, br s), 4.28 (1H, br s), 6.78 (1H, s), 7.30 (3H, m), 7.45-7.5 (2H, m), 8.02 (1H, br s), 8.7 (2H, d, J=6).

Example 3

15

1-(4-bromo-3-methylbenzoyl)-5-methoxy-6-(4-methyl-1-piperazinyl)-1H-indole

To a mixture of intermediate 2 (0.25g, 1.0 mmol) and potassium t-butoxide (0.114g, 1 mmol) in dry THF (15 ml) was added 4-bromo-3-methyl benzoyl chloride (0.238g, 1.0 mmol) in dry THF (10 ml). The resulting mixture was stirred at room temperature for 72h, then poured onto water and extracted with dichloromethane (3x). The organic layers were combined, dried (Na₂SO₄), filtered and concentrated *in vacuo* to give the crude product. Purification by Fcc eluting with 3% methanol/dichloromethane gave the title compound as a pale yellow oil (70 mg, 15%).

25

¹H NMR (250 MHz, CDCl₃) δ :

2.41 (3H, s), 2.49 (3H, s), 3.12 (4H, br s), 3.44 (4H, br s), 3.92 (3H, s), 6.5 (1H, d, J=2), 7.03 (1H, s), 7.12 (1H, d, J=2), 7.39 (1H, d, J=6), 7.53 (1H, m), 7.58 (1H, s), 7.68 (1H, d, J=6).

30

Example 4**2,3-Dihydro-5-methoxy-6-(4-methyl-1-piperazinyl)-1-[2'-bromo-3'-methoxy-thiophene-4'-ylcarbonyl]indole**

5

A solution of intermediate 4 (0.2g) in a mixture of THF (5ml) and aqueous sodium hydroxide (0.1g in 5ml of H₂O) was treated with a solution of 4-bromo-3-methoxythiophene-2-carboxylic acid chloride (0.31g) in THF (5ml). The reaction mixture was stirred at room temperature for 10 hours, poured into water, and extracted with
10 dichloromethane. The combined organic extracts were dried over sodium sulphate and concentrated in vacuo to give the title compound as a brown oil (0.21g, 53%).

¹H NMR (250MHz, CDCl₃) δ :

15 2.40 (3H s), 2.67 (4H, br s), 3.04-3.17 (6H, m), 3.82-4.02 (8H, m), 6.78 (1H, s), 7.41 (1H, s), 8.01 (1H, s)

Example 5**2,3-Dihydro-5-methoxy-6-(4-methyl-1-piperazinyl)-1-[4'-phenoxybenzoyl]indole**

A solution of intermediate 4, (0.2g) in THF (2ml) and sodium hydroxide (0.1g in 2ml H₂O) was treated with a solution of 4-phenoxybenzoyl chloride (0.28g) in THF (5ml). The reaction was stirred overnight, poured into water and extracted with dichloromethane.
25 The combined extracts were dried over sodium sulphate and concentrated to give an oil which was purified by column chromatography using CH₂Cl₂ to 96% CH₂Cl₂/4% MeOH as eluent. The title compound was obtained as a pale yellow oil.

¹H NMR (250 MHz, CDCl₃) δ :

30

2.41 (3H, s), 2.69 (4H, br s), 2.97-3.14 (6H, m), 3.84 (3H, s), 4.11 (2H, br s), 6.77 (1H, s), 6.95-7.08 (5H, m), 7.19 (1H, t, J=6), 7.39 (2H, t, J=6), 7.53 (2H, d, J=6).

Example 6

2,3-Dihydro-5-methoxy-1-[4-(2-methyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)benzoyl]-6-(4-methyl-1-piperazinyl)-1H-indole

- 5 2'-Methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-carboxylic acid (EP 0 533 268 A1 - Intermediate 42) (410 mg, 0.0014 mole) was treated with thionyl chloride (15 ml) and heated under reflux for 2h. The solution was concentrated *in vacuo* to leave the acid chloride as a yellow oil. This was dissolved in dry THF (5 ml) and added at room temperature to a stirred solution of intermediate 3 (300 mg, 0.0012 mole) in THF (20 ml)
- 10 and H₂O (10 ml) containing sodium hydroxide (100 mg, 0.0024 mole). The mixture was stirred at room temperature for 20 h, then concentrated *in vacuo* to approx. 15 ml volume and extracted with dichloromethane (2 x 40 ml). The combined extracts were dried (Na₂SO₄) and concentrated *in vacuo* to leave a yellow oil, which was crystallised from ethyl acetate/60-80 petrol to afford the title compound as a beige solid (500 mg, 80%), mp
- 15 213-214°C.

¹H NMR (270 MHz, 80° C, CDCl₃)

- δ : 7.97 (1H, s), 7.93 (1H, d), 7.60 (2H, d), 7.40 (2H, d), 7.31 (1H, d), 6.73 (1H, s), 4.13
- 20 (2H, t), 3.82 (3H, s), 3.05 (2H, t), 2.97 (4H, br s), 2.63 (3H, s), 2.47-2.55 (4H, m), 2.34 (3H, s), 2.29 (3H, s), 1 aromatic proton too broad to observe.

Example 7

- 5-Methoxy-1-[4-(2-methyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)benzoyl]-6-(4-methyl-1-piperazinyl)-1H-indole**
- 25

- A stirred solution of intermediate 2 (300 mg, 0.0012 mole) in dry THF (30 ml) under argon was treated with potassium t-butoxide (140 mg, 0.0012 mole) and kept at room temperature for 20 minutes. The resulting mixture was treated with a solution of 4-[2-methyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl] benzoyl chloride (0.0014 mole) in dry
- 30 THF (10 ml) and the mixture stirred at room temperature for 20h. The solution was concentrated *in vacuo* and the residue treated with 10% Na₂CO₃ solution (20 ml) and extracted with dichloromethane (2 x 40 ml). The combined extract was dried (Na₂SO₄), concentrated *in vacuo* and the residue chromatographed on silica gel eluting with 0-3% methanol/dichloromethane. The title compound was obtained as a yellow solid on
- 35 crystallisation from ethyl acetate/60-80 petrol (220 mg, 35%) mp 175-177° C.

¹H NMR (250 MHz, CDCl₃)

5 δ : 2.39 (6H, s), 2.68 (7H, br s), 3.20 (4H, br s), 3.95 (3H, s), 6.55 (1H, d), 7.05 (1H, s),
7.28 (1H, d), 7.38 (1H, d), 7.51 (2H, d), 7.82 (2H, d), 7.99 (1H, d), 8.04 (1H, s), 8.10
(1H, s)

Example 8

**2,3-Dihydro-5-methoxy-1-[4-(2-methyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)
benzoyl]-6-(1-piperazinyl)-1H-indole**

10


2'-Methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-carboxylic acid (EP 0 533
268 A1 Intermediate 42) (205 mg, 0.70 mmole) was treated with thionyl chloride (5 ml)
and heated under reflux for 2h. The solution was concentrated under vacuum to leave the
acid chloride as a yellow oil. This was dissolved in dry THF (5 ml) and added to a stirred
15 solution of intermediate 5 (205 mg, 0.61 mmole) in THF (5 ml) and H₂O (5 ml)
containing NaOH (56 mg, 1.4 mmole). The mixture was stirred at room temperature for
0.5 h, then diluted with H₂O (20 ml) and extracted with ethyl acetate (2 x 25 ml). The
combined extract was dried (Na₂SO₄) and concentrated under vacuum. The residual
material crystallised from ethyl acetate/ether to afford a white solid (280 mg). This was
20 dissolved in methanol (10 ml), treated with ether/HCl (2 ml of 3.3M solution) and left at
room temperature for 20 h. The solid which had crystallised out was filtered off and dried
to afford the hydrochloride salt of the title compound as a beige solid (190 mg) mp 153-
155° C.

25 HCl salt:- ¹H NMR (250 MHz) d⁶DMSO

δ : 9.45 (2H, br s), 7.87-8.00 (3H, m), 7.68 (2H, br d), 7.52 (2H, d), 7.45 (1H, d),
7.00 (1H, s), 4.06 (2H, br t), 3.80 (3H, s), 3.10-3.35 (8H, br s), 3.05 (2H, t), 2.69 (3H, s),
2.37 (3H, s).


CLAIMS:

1. A compound of formula (I) or a salt thereof:



in which


R is a group of formula (i):



in which P¹ is a phenyl or a 5 to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen or sulphur; and

R¹ and R² are independently hydrogen, halogen, C₁₋₆alkyl, C₁₋₆alkoxy, hydroxyC₁₋₆alkyl, acyl, nitro, trifluoromethyl, cyano, SR⁵, SOR⁵, SO₂R⁵, SO₂NR⁵R⁶, CO₂R⁵, CONR⁵R⁶, CONR⁵(CH₂)_xCO₂R⁶, NR⁵R⁶, NR⁵CO₂R⁶, CR⁵=NOR⁶, where R⁵ and R⁶ are independently hydrogen or C₁₋₆alkyl and x is 1 to 3;

or R is a group of formula (ii):



in which P² is phenyl or biphenyl;

P³ is phenyl or a 5 to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen or sulphur;

A is a bond or a group (CH₂)_p-R⁸-(CH₂)_q where R⁸ is oxygen, S(O)_m where m is 0 to 2, carbonyl, CO₂ or CH and p and q are independently 0 to 3; and

R¹ and R² are as defined above in formula (i);

R³ is hydrogen, halogen, hydroxy, C₁₋₆alkyl or C₁₋₆alkoxy;

n is 1 or 2;

R⁴ is hydrogen or C₁₋₆alkyl; and

B is -CHR⁹CHR¹⁰- or -CR⁹=CR¹⁰- where R⁹ and R¹⁰ are independently hydrogen or C₁₋₆alkyl.


2. A compound according to claim 1 in which R is a group of formula (ii).
3. A compound according to claim 2 in which P² is biphenyl and P³ is an oxadiazolyl group.
4. A compound according to claim 2 or 3 in which R¹ and R² are
- 5 C₁₋₆alkyl.
5. A compound according to any one of claims 1 to 4 in which R³ is C₁₋₆alkoxy.
6. A compound according to any one of claims 1 to 5 in which R⁴ is hydrogen or C₁₋₄alkyl.
- 10 7. A compound according to claim 1 which is:
 1-[3-methyl-4-(4-pyridyl)phenyl]-2,3-dihydro-5-methoxy-6-(4-methyl-1-piperazinyl)-1H-indole,
 1-(4-bromo-3-methylbenzoyl)-2,3-dihydro-5-methoxy-6-(4-methyl-1-piperazinyl)-1H-indole,
 15 1-(4-bromo-3-methylbenzoyl)-5-methoxy-6-(4-methyl-1-piperazinyl)-1H-indole,
 2,3-dihydro-5-methoxy-6-(4-methyl-1-piperazinyl)-1-[2'-bromo-3'-methoxythiophene-4'-ylcarbonyl]indole,
 2,3-dihydro-5-methoxy-6-(4-methyl-1-piperazinyl)-1-[4'-phenoxybenzoyl]indole,
 2,3-dihydro-5-methoxy-1-[4-(2-methyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)benzoyl]-6-(4-methyl-1-piperazinyl)-1H-indole,
 20 benzoyl]-6-(4-methyl-1-piperazinyl)-1H-indole,
 5-methoxy-1-[4-(2-methyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)benzoyl]-6-(4-methyl-1-piperazinyl)-1H-indole, or
 2,3-dihydro-5-methoxy-1-[4-(2-methyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)benzoyl]-6-(1-piperazinyl)-1H-indole,
 25 or pharmaceutically acceptable salts thereof.
8. A process for the preparation of a compound of formula (I) which comprises:
- (a) coupling a compound of formula (II):

30

R-COL

(II)


in which R is as defined in formula (I) and L is a leaving group with a compound of
 35 formula (III):



(III)

5 in which R^3 , R^4 , B and n are as defined in formula (I);

(b) for compounds where R is a group of formula (ii), A is a bond and P^2 is a phenyl group, reaction of a compound of formula (IV):




(IV)

10 in which R^2 , R^3 , R^4 and n are as defined in formula (I), P^2 is phenyl and X is a leaving group with a nucleophile R^1-P^3 where R^1 and P^3 are as defined in formula (I);

15

(c) reaction of a compound of formula (V):



(V)

20


in which R, R^3 , B and n are as defined in formula (I) with a compound of formula (VI):



25


in which R^4 is as defined in formula (I) and Hal is halogen, or

(d) for compounds where R is a group of formula (ii) and A is a bond, reaction of a compound of formula (VII):



(VII)


in which P², R², R³, R⁴, B and n are as defined in formula (I) and Y is halogen or a group -OSO₂CF₃ with a compound of formula (VIII):



(VIII)


15 in which R¹ and P³ are as defined in formula (I), or

(e) for compounds where R is a group of formula (ii) and A is a bond, reaction of a compound of formula (IX):



(IX)

in which P², R², R³, R⁴, B and n are as defined in formula (I) with a compound of formula (X):



(X)

in which R¹ and P³ are as defined in formula (I) and Y is as defined in formula (VII), and optionally after any of the above processes:

- converting a compound of formula (I) into another compound of formula (I)
- forming a pharmaceutically acceptable salt.

5 9. A compound according to any one of claims 1 to 7 for use in therapy.

10. A pharmaceutical composition which comprises a compound according to any one of claims 1 to 7 in association with a pharmaceutically acceptable carrier or excipient.

INTERNATIONAL SEARCH REPORT

Application No
PCT/EP 94/02663

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D209/08 C07D401/10 C07D409/10 C07D413/10 A61K31/40

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO,A,84 02133 (KATHOLIEKE UNIVERSITEIT THE LEUVEN) 24 November 1983 *Page 10: line 10-18* ---	1
A	CHEMICAL ABSTRACTS, vol. 68, no. 15, 8 April 1968, Columbus, Ohio, US; abstract no. 68881x, page 6645 ;column R ; see abstract & HU,A,153 386 (EGYESULT GYOYSZER ES TAPSZERGYAR) 23 January 1967 --- -/--	1

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

5 January 1995

Date of mailing of the international search report

13.01.95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Luyten, H

INTERNATIONAL SEARCH REPORT

Intern. Application No

PCT/JP 94/02663

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CHEMICAL ABSTRACTS, vol. 69, no. 23, 2 December 1968, Columbus, Ohio, US; abstract no. 96381y, page 9012 ;column L ; see abstract & ACTA CHIM. SCI. HUNG., vol.56, no.3, 1968 pages 311 - 313 ----	1
A	EP,A,0 533 268 (GLAXO GROUP LIMITED) 24 March 1993 cited in the application *Page 33-39: claims* ----	1-10
A	EP,A,0 533 267 (GLAXO GROUP LIMITED) 24 March 1993 cited in the application *Page 31-35: claims* ----	1-10
A	EP,A,0 533 266 (GLAXO GROUP LIMITED) 24 March 1993 cited in the application *Page 36-42: claims* -----	1-10

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 94/02663

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-8402133	07-06-84	LU-A- 84492	13-06-84
		AU-A- 2261383	18-06-84
		EP-A- 0127634	12-12-84

HU-A-153386		NONE	

EP-A-0533268	24-03-93	AP-A- 303	28-01-94
		AU-A- 2453092	25-03-93
		CA-A- 2078505	19-03-93
		HU-A- 65608	28-07-94
		JP-A- 6116251	26-04-94
		US-A- 5340810	23-08-94
		CN-A- 1076195	15-09-93

EP-A-0533267	24-03-93	AU-A- 2452892	25-03-93
		AU-A- 2568792	27-04-93
		CA-A- 2078507	19-03-93
		CN-A- 1073430	23-06-93
		WO-A- 9306084	01-04-93
		FI-A- 941261	17-03-94
		JP-A- 6107637	19-04-94
		NO-A- 940974	17-03-94
		US-A- 5358948	25-10-94

EP-A-0533266	24-03-93	AU-A- 2452992	25-03-93
		CA-A- 2078506	19-03-93
		HU-A- 66319	28-11-94
		JP-A- 6107649	19-04-94
		US-A- 5356893	18-10-94
